A Phase II/III Randomized, Double-Blind, Placebo Controlled Trial of a Nucleoside Supplementation In HIV Lipoatrophy.

The study will try to see if taking a nucleoside supplement is safe in HIV-infected persons and if it will reverse the loss of fat in the face, arms, legs, or buttocks. The study will also try to see how well the nucleoside drug is tolerated. The study drug is a powdered nutritional supplement that contains a substance belonging to a nucleoside. It comes in a sachet (packet) and needs to be mixed with juice, milk, or water. The study drug is used in Europe as a food supplement but is not approved by the U.S. Food and Drug Administration (FDA) and is considered an experimental drug in the United States.

• Men and women who are at least 18 years old
• HIV-1 infection
• Cumulative duration of thymidine NRTI (ZDV or d4T) treatment for at least 24 weeks prior to study entry.
• HIV-1 RNA 5000 copies/mL or less obtained within 45 days prior to study entry